SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-23-016258
Filing Date
2023-05-08
Accepted
2023-05-08 07:50:26
Documents
81
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q akba-20230331.htm   iXBRL 10-Q 1753921
2 EX-10.1 exhibit101-amendedandresta.htm EX-10.1 28631
3 EX-10.2 exhibit102-akebiasiegfried.htm EX-10.2 45037
4 EX-10.3 exhibit103-formofakebia201.htm EX-10.3 50207
5 EX-31.1 exhibit311-q12023.htm EX-31.1 11363
6 EX-31.2 exhibit312-q12023.htm EX-31.2 11436
7 EX-32.1 exhibit321-q12023.htm EX-32.1 9304
  Complete submission text file 0001628280-23-016258.txt   7884786

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT akba-20230331.xsd EX-101.SCH 75462
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT akba-20230331_cal.xml EX-101.CAL 68399
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT akba-20230331_def.xml EX-101.DEF 313521
11 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT akba-20230331_lab.xml EX-101.LAB 688283
12 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT akba-20230331_pre.xml EX-101.PRE 458143
75 EXTRACTED XBRL INSTANCE DOCUMENT akba-20230331_htm.xml XML 1047995
Mailing Address 245 FIRST STREET CAMBRIDGE MA 02142
Business Address 245 FIRST STREET CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Filer) CIK: 0001517022 (see all company filings)

IRS No.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36352 | Film No.: 23895890
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences